U.S. Markets closed

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1300+0.0100 (+0.89%)
At close: 4:00PM EDT
1.1150 -0.01 (-1.33%)
After hours: 05:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1200
Open1.1200
Bid1.1000 x 1000
Ask1.1300 x 800
Day's Range1.1000 - 1.1400
52 Week Range1.0100 - 2.9800
Volume391,917
Avg. Volume792,457
Market Cap59.581M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-0.5930
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.98
  • Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
    GlobeNewswire

    Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.

    Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has expanded its ongoing collaboration with IntoCell Inc., a biotechnology company based in South Korea. The parties have been collaborating on combinin

  • Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
    GlobeNewswire

    Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)

    Development of Multiple Novel PDCsFLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has entered into a development and commercialization collaboration with LegoChemBio, a clinical stage South Korea-based biotechnology company, for the development and commercialization of novel first-in-class phosphol

  • Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
    GlobeNewswire

    Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

    FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conference: Ladenburg Thalmann 2021 Virtual Healthcare ConferencePresentation Date: July 14, 2021Presentation Time: 3:00 pmWebcas